Ra Capital Management, L.P. Sells 128,770 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 128,770 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $0.39, for a total transaction of $50,220.30. Following the completion of the transaction, the insider owned 341,353 shares in the company, valued at approximately $133,127.67. The trade was a 27.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. sold 149,625 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $55,361.25.
• On Friday, June 12th, Ra Capital Management, L.P. sold 170,441 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $68,176.40.
• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Stock Down 4.4%

Shares of NASDAQ:HOWL opened at $0.34 on Thursday. The company has a market cap of $16.72 million, a PE ratio of -0.28 and a beta of 0.29. The company’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.70. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.34 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Regal Investment Advisors LLC raised its stake in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. raised its stake in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $48,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on HOWL shares. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.